Concordance analysis of IHC and FISH in the detection of ROS1 gene rearrangement in NSCLC: Results of a meta-analysis

被引：0
|
作者：
Godre, N. [1 ]
Gupta, V. [1 ]
Alam, M. [2 ]
机构：
[1] Pfizer India, Med Affairs Oncol, Mumbai, Maharashtra, India
[2] Pfizer Innovat Hlth, Med Affairs Oncol, Sydney, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
458P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A case report of ROS1 fusion detection by FISH - a possibility of false positive results
    Siemanowski, J.
    Heydt, C.
    Schultheis, A.
    Merkelbach-Bruse, S.
    VIRCHOWS ARCHIV, 2020, 477 : S38 - S38
  • [22] Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC
    Sorensen, J. B.
    Urbanska, E.
    Melchior, L.
    Santoni-Rugiu, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1094 - S1094
  • [23] High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Xu, Yuyin
    Chang, Heng
    Wu, Lijing
    Zhang, Xin
    Zhang, Ling
    Zhang, Jing
    Li, Yuan
    Shen, Lei
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 117
  • [24] Clinicopathological Data's of Advanced NSCLC Patients with ROS1 Gene Rearrangement and of Clinical Responses to Crizotinib in TURKEY
    Oz, Buge
    Batur, Sebnem
    Eralp, Yesim
    Hasturk, Serap
    Yumuk, Fulden
    Yildiz, Ozcan
    Karaoglu, Aziz
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S695 - S695
  • [25] Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis
    Wang, Zili
    Yang, Haitao
    Luo, Shuimei
    Liu, Bo
    Zhang, Nianhai
    Li, Lina
    Zhou, Sijing
    Shen, Ruifen
    Xie, Xianhe
    LUNG CANCER, 2017, 112 : 1 - 9
  • [26] Thromboembolism in ALK+ and ROS1+NSCLC patients: A systematic review and meta-analysis
    Zhu, Viola W.
    Zhao, Joseph J.
    Gao, Yanfei
    Syn, Nicholas L.
    Zhang, Shannon S.
    Ou, Sai-Hong Ignatius
    Bauer, Kenneth A.
    Nagasaka, Misako
    LUNG CANCER, 2021, 157 : 147 - 155
  • [27] Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis
    Zhang, Xia
    Zhou, Jian-Guo
    Wu, Hua-Lian
    Ma, Hu
    Jiang, Zhi-Xia
    ONCOTARGET, 2017, 8 (43) : 75400 - 75410
  • [28] CLINICAL ACTIVITY OF CRIZOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING ROS1 GENE REARRANGEMENT
    Bang, Y. -J.
    Ou, S.
    Camidge, D. R.
    Clark, J. W.
    Wilner, K.
    Tye, L.
    Stephenson, P.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 33 - 33
  • [29] Clinical Activity Of Crizotinib In Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement
    Shaw, A. T.
    Camidge, D.
    Clark, J. W.
    Wilner, K.
    Tye, L.
    Stephenson, P.
    Varella-Garcia, M.
    Iafrate, A.
    Ou, S. I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S208 - S209
  • [30] Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
    Fan, Y.
    Drilon, A.
    Chiu, C. -H.
    Bowles, D. W.
    Loong, H. H. F.
    Siena, S.
    Goto, K.
    Krzakowski, M.
    Ahn, M. -J.
    Murakami, H.
    Dziadziuszko, R.
    Zeuner, H.
    Pitcher, B.
    Cheick, D.
    Krebs, M. G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S89 - S90
12345